Best Available Treatment is named as a drug or biological intervention in 3 clinical trials in our UK, USA and China trial registers, 3 of which are recruiting. Lead sponsors include Incyte Corporation (2) and Union Hospital, Tongji Medical College, Huazhong University of Science and Technology (1). Registered phases: Phase 2 and Phase 3. Conditions studied include Chronic Graft-versus-host-disease; Essential Thrombocythemia; Steroid-Refractory Acute Graft-Versus-Host Disease.
| NCT ID | Study | Phase | Status |
|---|---|---|---|
| NCT07623200 | A Phase 3 Study of INCA033989 Versus Best Available Therapy in Participants With Essential Thrombocythemia (ClinicalTrials.gov ↗) Essential Thrombocythemia |
Phase 3 | Recruiting |
| NCT07124078 | A Study to Evaluate Axatilimab Versus Best Available Therapy in Pediatric Participants With Chronic Graft-Versus-Host Disease After at Least 2 Prior Lines of Systemic Therapy (AGAVE-256) (ClinicalTrials.gov ↗) Chronic Graft-versus-host-disease |
Phase 2 | Recruiting |
| NCT07572669 | Moxibustion for Steroid-Refractory Acute Graft-Versus-Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation (ClinicalTrials.gov ↗) Steroid-Refractory Acute Graft-Versus-Host Disease, Acute Graft-Versus-Host Disease, Graft-Versus-Host Disease |
Phase 2 | Recruiting |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Condition (as registered) | Trials |
|---|---|
| Chronic Graft-versus-host-disease | 1 |
| Essential Thrombocythemia | 1 |
| Steroid-Refractory Acute Graft-Versus-Host Disease | 1 |
| Acute Graft-Versus-Host Disease | 1 |
| Graft-Versus-Host Disease | 1 |
| Allogeneic Hematopoietic Stem Cell Transplantation | 1 |
| Lead sponsor | Trials |
|---|---|
| Incyte Corporation | 2 |
| Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | 1 |
| Register | Best Available Treatment trials |
|---|---|
| Clinical trials in UK | 2 |
| Clinical trials in USA | 2 |
| Clinical trials in China | 1 |
A trial with sites in more than one country appears in each of those registers.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Best Available Treatment works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Best Available Treatment (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 24 Sep 2026.